Myosin Inhibition in Non-obstructive Hypertrophic Cardiomyopathy: Lessons from ODYSSEY-HCM
European Cardiology Review · 15.06.2026
DOI: 10.15420/ecr.2026.17 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift European Cardiology Review, online erschienen am 15.06.2026. Verfasst von Koji Hasegawa und 3 weiteren Autor:innen. Beteiligte Einrichtung: National Hospital Organization Kyoto Medical Center Kyoto, Japan. Die Arbeit nennt 7 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0).
Abstract (Originalsprache)
The Phase III ODYSSEY-HCM trial evaluating the cardiac myosin inhibitor mavacamten in symptomatic non-obstructive hypertrophic cardiomyopathy did not demonstrate significant improvements in clinical endpoints, including the Kansas City Cardiomyopathy Questionnaire score and peak oxygen consumption. However, mavacamten significantly reduced pro-B-type natriuretic peptide levels and improved echocardiographic indices of diastolic and left atrial function, suggesting a potential biological effect. This apparent dissociation between biomarker improvement and clinical outcomes raises questions regarding patient selection, endpoint choice and dosing strategy. In addition, the observed decline in left ventricular systolic function in a substantial proportion of treated patients may have offset the benefits of improved diastolic performance and may have implications for arrhythmic vulnerability. In this viewpoint, the ODYSSEY-HCM trial is critically appraised and future directions for optimising myosin inhibition therapy in non-obstructive hypertrophic cardiomyopathy are discussed.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- National Hospital Organization Kyoto Medical Center Kyoto, Japan.
- Carol Davila University of Medicine, Academy of the Romanian Scientists Bucharest, Romania.
Zitieren
APA
Hasegawa, K., Iguchi, M., Wada, H., & Dan, G. A. (2026). Myosin Inhibition in Non-obstructive Hypertrophic Cardiomyopathy: Lessons from ODYSSEY-HCM. European Cardiology Review. https://doi.org/10.15420/ecr.2026.17
Vancouver
Hasegawa K, Iguchi M, Wada H, Dan GA. Myosin Inhibition in Non-obstructive Hypertrophic Cardiomyopathy: Lessons from ODYSSEY-HCM. European Cardiology Review. 2026. doi:10.15420/ecr.2026.17
BibTeX
@article{Hasegawa2026,
author = {Hasegawa, Koji and Iguchi, Moritake and Wada, Hiromichi and Dan, Gheorghe-Andrei},
title = {Myosin Inhibition in Non-obstructive Hypertrophic Cardiomyopathy: Lessons from ODYSSEY-HCM},
journal = {European Cardiology Review},
year = {2026},
doi = {10.15420/ecr.2026.17}
}
EUVIMED